关于奥园美谷科技股份有限公司 内部控制审计报告 众环审字（2025）0103163号 目录 起始页码 内部控制审计报告 l in the : " 内部控制审计报告 众环审字(2025) 0103163 号 奥园美谷科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了奥 园美谷科技股份有限公司(以下简称"奥园美谷公司")2024年12月31日的财务报告内部 控制的有效性。 一、奥园美谷公司对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》 的规定,建立健全和有效实施内部控制,并评价其有效性是奥园美谷公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审计意见, 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情况的变化 可能导致内部控制变得不恰当,或对控制政策和程序遵循的程度降低,根据内部控制审计结 果推测未来内部控制的有效性具有一定风险。 are and the ...

Core Viewpoint - The pharmaceutical distribution giant Jiuzhoutong announced its acquisition of a 20% stake in Aoyuan Meigu for 673 million yuan, aiming to become a potential controlling shareholder post-restructuring, marking a strategic shift from a medical beauty supply chain service provider to an operator of terminal medical institutions [1][2]. Group 1: Acquisition Details - Jiuzhoutong's wholly-owned subsidiary signed an investment agreement to acquire 360 million shares of Aoyuan Meigu, which is undergoing restructuring [2]. - Aoyuan Meigu, despite having well-known medical beauty resources, has faced continuous losses and is in a state of insolvency, prompting Jiuzhoutong to leverage its experience in the medical beauty industry to revitalize this asset [1][6]. Group 2: Industry Context - Aoyuan Meigu, originally listed as Hubei Jinhui in 1996, has undergone multiple ownership changes and business transformations, entering the medical beauty sector in 2020 under Aoyuan Group [6]. - The company has struggled financially, with projected losses of 320 million to 450 million yuan for 2024, leading to its restructuring application in November 2024 [6]. Group 3: Jiuzhoutong's Strategy - Jiuzhoutong has been active in the medical beauty sector since 2016, investing in companies like Aimeike and forming strategic partnerships with major players like Huaxi Biological and Langzi Medical [7][8]. - The company has seen its medical beauty segment revenue double to 342 million yuan in 2023, indicating significant growth potential despite challenges in its core pharmaceutical distribution business [9][11]. Group 4: Financial Performance - Jiuzhoutong's revenue increased from 118.06 billion yuan in 2020 to 150.14 billion yuan in 2023, but net profit declined from 3.075 billion yuan to 2.174 billion yuan during the same period, highlighting the pressures on its traditional business [9][11]. - The company has raised over 6 billion yuan through various financing methods since its listing in 2010, demonstrating its financial flexibility to support new ventures [11]. Group 5: Future Outlook - The successful restructuring of Aoyuan Meigu could allow Jiuzhoutong to transition from a supplier to a terminal service operator, leveraging its supply chain advantages and Aoyuan Meigu's member resources for enhanced product penetration [12]. - The strategic shift into the medical beauty sector is critical for Jiuzhoutong's future growth trajectory and market positioning, as it seeks to establish a second growth curve amid slowing traditional business growth [12].

Core Viewpoint - 九州通, a leading company in the pharmaceutical distribution industry, has announced its participation in the restructuring of Aoyuan Meigu (ST Meigu), aiming to become its controlling shareholder by investing 673 million yuan for 360 million shares post-restructuring [1][5]. Group 1: 九州通 Overview - 九州通's main business includes pharmaceutical distribution, CSO, pharmaceutical manufacturing, and new retail, with a focus on the medical aesthetics sector [5]. - In 2023, 九州通's medical aesthetics business achieved sales revenue of 342 million yuan, a year-on-year increase of 103.06% [5]. - The company reported a total revenue exceeding 150 billion yuan in 2023, with the medical aesthetics segment contributing a relatively small portion [5]. Group 2: Aoyuan Meigu Overview - Aoyuan Meigu's main businesses are bio-based fiber and medical beauty services, previously a regional leader in the medical aesthetics industry [1]. - Aoyuan Meigu has developed well in the medical aesthetics sector, operating several medical beauty hospitals and health management consulting companies [5]. Group 3: Strategic Implications - 九州通 believes that Aoyuan Meigu's medical beauty services will synergize well with its own medical aesthetics business, enhancing overall competitiveness in the beauty and health industry [5]. - The company plans to leverage its supply chain system, operational management experience, and digital capabilities to collaborate with Aoyuan Meigu in various areas, including supply chain integration and core product development [5]. Group 4: Financial Performance - 九州通's financial performance for the first three quarters of 2024 showed a slight decline, with revenue of approximately 113.4 billion yuan, down 0.82% year-on-year, and a net profit of about 1.696 billion yuan, down 6.99% year-on-year [8]. - The implementation of the restructuring investment agreement is subject to the court's approval of Aoyuan Meigu's restructuring plan, indicating uncertainty in the investment's outcome [8].

Core Viewpoint - ST Meigu's restructuring has attracted significant interest from investors, with Tianjin Xinmeitong and Hubei Jiuzhou Industrial Park Management Company set to become the main investors, aiming to revitalize the company amid its financial difficulties [1][4]. Group 1: Restructuring Details - Tianjin Xinmeitong and Hubei Jiuzhou are the selected investors for ST Meigu's restructuring, with Jiuzhou expected to become the controlling shareholder post-restructuring [1]. - Jiuzhou plans to invest 673.2 million yuan to acquire 360 million shares at a price of 1.87 yuan per share, which is 50% of the market reference price [2]. - Tianjin Xinmeitong will also acquire 100 million shares at the same price, totaling 187 million yuan [2]. Group 2: Financial Performance and Challenges - ST Meigu is facing significant financial losses, with a projected net loss of 320 million to 450 million yuan for 2024 [4]. - The company has had its bank accounts frozen due to litigation and overdue debts, leading to additional trading risks [4]. - Despite these challenges, the medical beauty service segment has shown strong revenue, contributing 58.82% of the total revenue in the first half of 2024 [5]. Group 3: Strategic Implications - Jiuzhou's investment aligns with its long-term strategic goals, particularly in the medical beauty sector, which has seen rapid growth [5]. - The medical beauty business of Jiuzhou reported a sales revenue of 342 million yuan in 2023, a 103.06% increase year-on-year [5]. - The restructuring process remains uncertain, with potential risks of court rejection or delisting by the end of 2025 [5].

Core Viewpoint - 九州通's subsidiary, Hubei Jiuzhou Industrial Park Operation Management Co., Ltd., signed a restructuring investment agreement with Aoyuan Meigu Technology Co., Ltd., planning to invest 673 million yuan to acquire 360 million shares post-restructuring [2][3] Group 1: Investment Details - The investment aims to make 九州通 the controlling shareholder of ST Meigu if the restructuring plan is successfully completed [3] - The restructuring investment is expected to positively impact 九州通's medical beauty business and align with its long-term strategic development plan [3] Group 2: Business Synergy - Aoyuan Meigu's medical beauty services have good synergy with 九州通's existing medical beauty operations, which have rapidly grown and now cover over 10,000 medical beauty service institutions nationwide [3] - 九州通 plans to leverage its strong pharmaceutical supply chain, efficient operational management, and advanced digital capabilities to enhance collaboration with Aoyuan Meigu in the beauty and health sector [3] Group 3: Implementation and Uncertainty - The specific implementation of the restructuring investment will depend on the court's approval of Aoyuan Meigu's restructuring plan [3] - There is uncertainty regarding the subsequent progress and effects of 九州通's participation in the restructuring investment, with no significant short-term impact on the company's operating performance [3]

证券代码：000615 证券简称：ST美谷 公告编号：2025-025 奥园美谷科技股份有限公司 关于与重整投资人签署《重整投资协议》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、公司已进入预重整程序，公司能否进入重整程序尚存在不确定性。 预重整程序是为了提前启动公司债权债务梳理等相关工作，提高后续重整 工作推进效率及重整可行性的程序。襄阳中院同意公司预重整，不代表法院正式 受理申请人对公司的重整申请，截至本公告披露日，公司尚未收到法院关于受理 重整申请的相关法律文书，即申请人的重整申请能否被法院受理、公司后续能否 进入重整程序均存在不确定性。敬请广大投资者注意投资风险。 重整或预重整是否成功也存在不确定性。法院决定受理预重整申请，也不代 表公司正式进入重整程序。如果公司预重整成功，法院将依法审查是否受理重整 申请，公司能否进入重整程序尚存在不确定性。敬请广大投资者注意投资风险。 2、法院受理重整申请后，公司股票交易存在被实施退市风险警示的风险。 根据《深圳证券交易所股票上市规则（2024 年修订）》（以下简称《股票上 市规则》） ...

奥园美谷科技股份有限公司 关于重大诉讼事项进展的公告 证券代码：000615 证券简称：ST美谷 公告编号：2025-024 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次案件所处的诉讼阶段：执行； 2、上市公司所处的当事人地位：被告； 3、目前，定向融资计划案件导致的非经营性资金占用余额为 0 元； 4、对上市公司损益产生的影响：公司将根据企业会计准则的相关规定和诉 讼案件等情况进行财务处理，具体处理结果以及对公司本期期末业绩的影响，以 会计师事务所最终年度审计结果为准。 5、敬请广大投资者关注风险提示内容，谨慎决策、注意投资风险。 一、诉讼案件的基本情况 1、信达资管案件的基本情况 信达资产管理股份有限公司广东省分公司（以下简称"信达资管"、原告） 因合同纠纷向成都市武侯区人民法院提起诉讼，诉讼请求为：判令被告京汉置业 集团有限责任公司偿还原告债务本金 163,677,923.79 元及重组宽限补偿金、违 约金；判令被告奥园美谷科技股份有限公司（以下简称"公司"）、重庆天池园 林开发有限公司、奥园集团有限公司、广州康威集团有限公司、惠 ...

证券代码：000615 证券简称：ST美谷 公告编号：2025-023 敬请广大投资者谨慎决策，注意投资风险。 一、关于公司股票交易可能被实施退市风险警示的情况说明 根据公司 2024 年业绩预告的财务数据，预计公司 2024 年度归属于上市公司 股东的净资产为-24,000 万元至-12,000 万元（负值），若 2024 年度经审计后的归 属于上市公司股东的净资产为负值，公司股票交易因此可能被实施退市风险警示 （股票简称前冠以"*ST"字样）。若触及《股票上市规则》第 9.3.1 条规定的其 他情形，公司股票交易同样因此被实施退市风险警示。 奥园美谷科技股份有限公司 关于公司股票交易可能被叠加实施退市风险警示及其他风险 警示的第二次提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、根据奥园美谷科技股份有限公司（以下简称"公司"）测算，公司预计 2024 年度归属于上市公司股东的净资产为负值。根据《深圳证券交易所股票上市规则 （2024 年修订）》（以下简称《股票上市规则》）第 9.3.1 条第（二）项的规定， 若公司 2024 年 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗漏。 特别风险提示： 1、截至本公告披露日，公司已进入预重整程序，公司尚未收到法院关于受理重整申请的相关法律文书，申请人的 重整申请能否被法院受理、预重整程序最终能否完成及后续能否进入重整程序均存在不确定性，敬请广大投资者 注意投资风险。 2、公司分别于2025年1月21日和3月22日披露了《关于公司股票交易可能被叠加实施退市风险警示及其他风险警示 的提示性公告》和《关于公司股票交易可能被叠加实施退市风险警示及其他风险警示的第一次提示性公告》，敬 请广大投资者注意投资风险。 3、敬请广大投资者关注本公告风险提示内容，注意投资风险。 一、股票交易异常波动情况 奥园美谷科技股份有限公司（以下简称"公司"）股票（证券简称：ST美谷，证券代码：000615）于2025年4月8 日、4月9日和4月10日连续三个交易日收盘价格跌幅偏离值累计超过12%，根据《深圳证券交易所交易规则》的有 关规定，属于股票交易异常波动的情况。 二、公司关注、核实情况说明 1、公司于2025年1月21日在 ...

证券代码：000615 证券简称：ST美谷 公告编号：2025-022 奥园美谷科技股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别风险提示： 1、截至本公告披露日，公司已进入预重整程序，公司尚未收到法院关于受 理重整申请的相关法律文书，申请人的重整申请能否被法院受理、预重整程序 最终能否完成及后续能否进入重整程序均存在不确定性，敬请广大投资者注意 投资风险。 2、公司分别于 2025 年 1 月 21 日和 3 月 22 日披露了《关于公司股票交易 可能被叠加实施退市风险警示及其他风险警示的提示性公告》和《关于公司股票 交易可能被叠加实施退市风险警示及其他风险警示的第一次提示性公告》，敬请 广大投资者注意投资风险。 3、敬请广大投资者关注本公告风险提示内容，注意投资风险。 一、股票交易异常波动情况 奥园美谷科技股份有限公司（以下简称"公司"）股票（证券简称：ST 美谷， 证券代码：000615）于 2025 年 4 月 8 日、4 月 9 日和 4 月 10 日连续三个交易日 收盘价格跌幅偏离值累计超过 12%， ...